AI주식인사이트AI Stock Insight
B

JW생명과학

234080KOSPI의약품 제조업

65.1 / 100

Reference Date: 2026-04-13

Financial Score31.5 / 40
News Sentiment15.6 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit metrics are weak. Slightly down 2.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

JW Life Science achieved sales of approximately 22.12 billion KRW in its 31st fiscal year, with its subsidiary JW Chungwa Pharmaceutical accounting for over 75.5% of total revenue. Through an exclusive licensing agreement with U.S.-based Baxter and EU-GMP certification for TPN production, the company is expanding its global IV solution market. Key products include basic, special, nutritional, and TPN IV solutions, with growth driven by overseas exports and B2B market expansion.

Number of Employees

319people

Average Salary

68.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
6.92Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR
0.92Industry Average 1.044.0Point

In line with industry avg

ROE
13.59Industry Average 4.427.0Point

3.1x industry avg (excellent)

Debt Ratio
5.98Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲11.7% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.5% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 18.9% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Detailed Momentum

52-week position3.0Point

52w lower range (39%)

Current 12,780Won52-week high 15,50052-week low 11,000
1-month return2.0Point

1m -2.74% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral주식등의대량보유상황보고서(약식)2026-04-07
  • Neutral기업가치제고계획(자율공시)2026-03-27
  • Neutral정기주주총회결과2026-03-26
  • Neutral사업보고서 (2025.12)2026-03-18
  • Neutral감사보고서제출2026-03-17